Affordable products for epilepsy patients arrives in Australia
MGC Pharma’s epilepsy product, CannEpil, touched down in Australia in late December.
This first shipment will be go to St Vincent’s Hospital in Melbourne, where a number of specialists were approved as Authorised Prescribers for the product in October 2018.
This could be a huge step forward for epilepsy patients seeking medicinal cannabis in Australia.
Generally, epilepsy requires high doses of CBD to see positive therapeutic benefits. This has led to the many reports of families having to pay tens of thousands of dollars per year for treatment, a number many cannot afford.
Due to this, many families are forced to abandon medicinal cannabis altogether, or turn back to the black market, for which there is no oversight on product safety.
Initial indications have shown the price of CannEpil is significantly cheaper than comparable products on the market, which will allow more patients to afford this potentially life-changing treatment.
MGC Pharma has also collaborated with Epilepsy Action Australia to develop C4E (cannabis for epilepsy), to provide education to epilepsy sufferers and their families on medicinal cannabis and its interaction with the illness.
Up to 25,000 Australians are diagnosed with epilepsy each year, and over 240,000 are living with epilepsy, according to Epilepsy Action Australia.
This shipment is also a significant milestone for medical cannabis and biopharma company (ASX:MXC), which has been steadily working on making CannEpil available in Australia.
Roby Zomer, CEO of MGC, said the milestone symbolised the completion of the final step before full commercialisation of its first investigational medicinal product (IMP).
“The arrival of CannEpil in Australia is a great achievement for us on our pathway to growing and commercialising the company as a European-based, pure biopharma company,” he said.
“We have been working extremely hard to get to this stage and we are all very excited to see the first sales of CannEpil achieved.”